C2i Genomics offers post-surgery monitoring of cancer recurrence and progression by analyzing subtle changes in the pattern of the tumor’s DNA
C2i Genomics offers post-surgery monitoring of cancer recurrence and progression by analyzing subtle changes in the pattern of the tumor’s DNA. Their AI-driven, whole-genome technology can analyze a small blood sample to detect minimal residual disease (MRD) in cancer patients.